Although both sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) ...

MADRID — Nearly half of people with type 2 diabetes (T2D) currently recommended to receive sodium-glucose cotransporter 2 (SGLT2) inhibitors for kidney protection would not actually benefit from them, ...

In late-breaking presentations at the American Society of Nephrology Kidney Week meeting and simultaneously published in two companion papers in JAMA, the findings are based on data from over 70,000 ...

SGLT2 inhibitors offer significant benefits in CKD and HF, yet remain underutilized in primary care settings. An interprofessional initiative developed a prescription algorithm to enhance SGLT2 ...

HOUSTON — The benefits of SGLT2 inhibitors in slowing kidney disease progression are similar regardless of patients’ type 2 diabetes (T2D) or albuminuria status, the results of a recent meta-analysis ...

Use of SGLT2 inhibitors rather than GLP-1 receptor agonists is associated with lower risk of progression to kidney replacement therapy among patients with type 2 diabetes and CKD. The risk of ...

Use of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO) organization's updated clinical practice guideline. In a synopsis of the recently ...

HOUSTON -- SGLT2 inhibitors may hold a benefit for a wider pool of patients with chronic kidney disease (CKD) than previously thought, a pair of meta-analyses indicated. SGLT2 inhibitors helped to ...

Diabetes is the most common cause of chronic kidney disease (CKD). Around 33 percent of adults with diabetes also have CKD. When diabetes causes CKD, its sometimes called diabetic kidney disease.